Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A pegylated form of Mechano Growth Factor, a splice variant of IGF-1 produced in response to mechanical stress on muscle tissue. The PEG (polyethylene glycol) modification extends the half-life from minutes to hours. Studied for muscle repair, hypertrophy, and recovery from injury. One of the 12 peptides removed from Category 2 in April 2026.
A synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in tissue repair and regeneration. Widely used in the biohacking community for injury recovery.
MGF is produced when muscle tissue is damaged or mechanically loaded. It activates satellite cells (muscle stem cells) and promotes their proliferation and differentiation into new muscle fibers. The PEG modification prevents rapid degradation, allowing sustained signaling. Works through the IGF-1 receptor but with distinct downstream effects from systemic IGF-1.
Promotes cell migration, blood vessel formation, and reduces inflammation. Upregulates actin, a cell-building protein critical for healing and cell migration to injury sites.
- Muscle repair and recovery
- Hypertrophy support
- Injury rehabilitation
- Age-related muscle loss (sarcopenia)
- Athletic recovery protocols
- Muscle and tendon repair
- Wound healing
- Reducing inflammation
- Hair regrowth (emerging research)
- Cardiac tissue repair
- Injection site pain and swelling
- Hypoglycemia risk
- Potential for uncontrolled cell proliferation
- Limited human safety data
- Banned by WADA in competitive sports
- Limited human clinical data
- Potential tumor growth concerns (theoretical)
- Injection site reactions
- Headaches reported anecdotally
Removed from Category 2 on April 22, 2026. Scheduled for PCAC Group 2 review (by February 2027). Not FDA-approved for any indication. Previously restricted under Category 2 since September 2023.
PCAC: 2027-02-01
On April 15, 2026, the FDA announced TB-500 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 to determine eligibility for the 503A bulk drug substances list. Compounding pharmacies should exercise caution until PCAC takes action.
PCAC: July 23, 2026
- Thymosin β4 promotes dermal healing
2007 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.